# Filing Detail

Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001193125-23-104996
Filing Date
2023-04-18
Accepted
2023-04-18 16:10:51
Documents
5
Period of Report
2023-06-07

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | PRE 14A | d464571dpre14a.htm | PRE 14A | 554765
2 | GRAPHIC | g464571g01a01.jpg | GRAPHIC | 78856
3 | GRAPHIC | g464571g02a02.jpg | GRAPHIC | 632077
4 | GRAPHIC | g464571page061.jpg | GRAPHIC | 150411
5 | GRAPHIC | g464571page062.jpg | GRAPHIC | 108511
| Complete submission text file | 0001193125-23-104996.txt |  | 1878960

Mailing Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021
Business Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Filer) CIK: 0000949858 (see all company filings)

EIN.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 033-80623 | Film No.: 23826958
SIC: 2835 In Vitro & In Vivo Diagnostic Substances